Business
Currency:CNY
2024/FY
Stock NameRevenueRatio
Pharmaceutical product sales8.23B87.33%
Authorization fee income1.1B11.68%
Income from R & D service charges93.78M1.00%
Product
Currency:CNY
2024/FY
Stock NameRevenueRatio
Pharmaceutical product sales8.23B87.33%
Authorization fee income1.1B11.68%
Income from R & D service charges93.78M1.00%
Region
Currency:CNY
2024/FY
Stock NameRevenueRatio
China8.98B95.35%
United States of America.411.59M4.37%
Other26.88M0.29%